Chapter
stringclasses 62
values | Section
stringclasses 571
values | Subsection
stringclasses 845
values | Subsubsection
stringclasses 240
values | Text
stringlengths 1
4.01k
|
|---|---|---|---|---|
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | distant metastasis, 499t, 502, 503 histologic grade included in, 503 primary tumor, 497t, 500, 502 prognostic groups, 500t |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | regional lymph nodes, 498t, 501 revisions to, 495 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | tumor staging, 447, 447f |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Toker cells, 840 Tomosynthesis |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | contrast-enhanced digital breast, 152–153 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | mammography, 150–151 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Toremifene, 619 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Total skin-sparing mastectomy. See |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Areolar-sparing mastectomy; Nipple- sparing mastectomy (NSM) |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | TP53, 183, 803 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Transarterial chemoembolization (TACE) outcome, 1061 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | selection criteria, 1060–1061 Transverse rectus abdominis |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | myocutaneous (TRAM) flap |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | for bilateral breast reconstruction, 543 breast cancer recurrence, 544–545 breast reconstruction using, 612, 613, |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | 1143 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | complications of, 544, 613 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | development of, 541 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | microsurgical/free, 543–544 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | pedicled technique, 542, 544 supercharged pedicled technique, 543 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Transverse upper gracilis flaps, 545 Trastuzumab, 1095–1097 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | adjuvant uses of, 521, 741, 742 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | anti-HER2 therapy, 747, 749 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | characteristics of, 434–435 cost analysis of, 1166 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | cytotoxic chemotherapy and, 961–964, 962t–963t |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | description of, 425 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | development of, 960–961 ductal carcinoma in situ |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | age, 349, 350t |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | biomarkers, 351 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | breast-conserving surgery alone, 346, 346t, 347t, 348 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | detection methods, 350 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | margin status, 348–349, 348t 349t pathologic features, 350–351 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | risk estimation of local recurrence, 352–353 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | risk factors for local recurrence, 348–351, 348t–350t |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | treatment era, 351 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | and EGFR tyrosine kinase inhibitors, 964 emtansine, 676 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | ERBB2-positive breast cancer treated with, 796 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | fluorescent in situ assays, 429 HER2-positive breast cancer |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | anthracycline vs. non-anthracycline regimens, 674 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | cardiac toxicity, 671–673 design and demographic |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | characteristics of, 668, 670 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | duration of, 673–674 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | early-stage benefits of, 671 FinHer study, 670 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | FNCLCC-PACS 04 study, 670–671 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | herceptin adjuvant, 669 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | markers of, 676–677 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | vs. sequential trastuzumab therapy, 673 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | HER2-targeting agents with endocrine therapy, 964 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | immunohistochemistry evaluations, 426 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | initial progression, 964–965 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | lapatinib, 967 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | locally advanced breast cancer treated with, 786 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | metastatic breast cancer treated with, 961 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | during pregnancy, 859, 860 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | resistance, 965 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | three-drug regimens with, 963t Trastuzumab-associated cardiotoxicity |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | doxorubicin vs., 731t mechanism, 730–731 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | risk factors, 731 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Treatment. See also specific modality |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | adverse events associated with tamoxifen, 283, 286, 287t–289t |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | biomechanics affected by, 585–586 emotional reactions to ending of, 1144 epidemiology of, 580, 582t, 583 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | fatigue caused by, 1129 impairments caused by, 579, 580t ovarian function effects, 1–3, |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | 1155–1157 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | patient selection for, 885 posture affected by, 585 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | prospective surveillance model, 587 range of motion activities affected by, |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | 583–584, 584t |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | surveillance after, 875–876 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | timing of, 586 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | upper quadrant disability after, 580 Treatment-related acute myelogenous |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | leukemia (t-AML), 735 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Trial Assigning Individualized Options for Treatment (TAILORx), 644, 644f |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Triple test |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | breast mass evaluation of, 34 definition of, 34 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Triple-negative breast cancers (TNBC) androgen receptor targets, 947 antitubulin agents, 946 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | description of, 740 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | EGFR inhibitors, 946 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | PARP inhibitors, 946–947 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | platinums, 945 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Src inhibitors, 947 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | taxanes, 945–946 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Tubular adenomas, 79 Tubular carcinoma |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | invasive carcinomas with ductal and lobular features |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | biomarkers, 388 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | clinical course, 388–389 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | clinical presentation, 387 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | gross pathology, 388 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | histopathology, 388, 388f |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | prognosis, 388–389 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | syringomatous adenoma of the nipple vs., 80 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Tumor. See also Breast tumors; Primary tumors |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | clinical measurement, 496 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | ductal intraepithelial neoplasia, 496 lobular intraepithelial neoplasia, 496 microscopic and gross measurement, |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | 495, 496 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Paget’s disease, 496 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Tumor biomarkers, utility scale for biological processes and end points, 441, |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | 441t |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | for clinical outcomes, 441, 442t levels of evidence, 441, 442t, 443t |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Tumor cell proliferation, S-phase fraction of, 448 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Tumor necrosis factor alpha (TNF), 728 Tumor size |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | breast-conserving therapy indications, 514 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | imaging of, 788 |